Las Vegas, Nevada — Cell MedX Corp. (OTCQB:CMXC), (the “Company”) announces the formation of an Advisory Board with Dr. John Sanderson MD as its Chairman. Dr. Sanderson will be organizing the development team and protocols necessary to advance the development of the Company’s proposed technology, including the clinical trial phases and oversight of the results of those trials. Dr. Sanderson is accepting this appointment as an interim position in the anticipation of joining the Company as its Chief Medical Director. Dr. Sanderson is a stem cell researcher who began his career in clinical medicine specializing in diabetes and intravenous nutrition of critically ill patients. He has received NIH funding, has multiple issued patents and published numerous academic papers as principal investigator. While a medical director and consultant at Johnson & Johnson, Dr. Sanderson was tasked with due diligence oversight for mergers and acquisitions, formulating strategic initiatives, and evaluating new technologies. As a consultant to Fortune 100 health care companies and the U.S. government, Dr. Sanderson worked with some of the greatest minds of the day devising technological solutions to important public health challenges such as obesity, diabetes, and asthma.
About Cell MedX Corp.
Cell MedX Corp. (the “Company”) is an early development stage company focused on the development and commercialization of therapeutic solutions for patients suffering the symptoms from diseases such as diabetes with technologies designed to help manage the complications commonly associated with these types of illnesses. The Company has entered into a binding agreement to acquire a proprietary technology for the treatment of diabetes and related ailments. The Company expects to complete the acquisition of this technology in November 2014.
On behalf of the Board of Directors,
Frank McEnulty, CEO of Cell MedX Corp.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company has not yet completed the acquisition of any technologies in its chosen field. Although the Company expects to complete the acquisition of a proprietary technology for the treatment of diabetes and related ailments, there is no assurance that the Company will be able to complete this acquisition in the expected time frame, on the expected terms or at all. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cellmedx Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
For further information about Cell MedX Corp. please visit the company’s website at http//:www.cellmedx.com. or phone us at 310-230-2300 x-1